普拉西泮治疗焦虑症：一项安慰剂对照的多中心评估。
Prazepam in the treatment of anxiety: a placebo-controlled multicenter evaluation.
作者信息
Weir J H
出版信息
J Clin Psychiatry. 1978 Dec;39(12):841-7.
A double-blind randomized multicenter parallel group comparison of prazepam in divided doses vs. placebo was conducted by 15 investigators among 847 patients presenting with anxiety alone or concurrent with other medical illnesses. Study groups were well matched for age, sex and level of pre-treatment symptomatology. Efficacy evaluation by a physician questionnaire included serial assessment of global improvement plus 10 target signs/symptoms during the 2 to 4 weeks of treatment. Prazepam was statistically significantly superior to placebo as shown on final on-treatment scores for global improvement ratio and for the target symptoms of anxiety, tension, irritability/hostility, depressive mood, insomnia and somatization.
15名研究人员对847例单纯患有焦虑症或同时患有其他疾病的患者进行了一项双盲随机多中心平行组对照研究，比较了分次服用普拉西泮与安慰剂的效果。研究组在年龄、性别和治疗前症状水平方面匹配良好。通过医生问卷进行的疗效评估包括在治疗的2至4周内对整体改善情况以及10项目标体征/症状进行系列评估。在整体改善率以及焦虑、紧张、易怒/敌意、抑郁情绪、失眠和躯体化等目标症状的最终治疗评分上，普拉西泮在统计学上显著优于安慰剂。
Zotero 插件